FDA approves Eli Lilly's Alzheimer’s drug that slows memory decline

The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with the disease, the drugmaker said Tuesday. The drug donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. The FDA cleared the drug for use in adults with mild cognitive impairment or early Alzheimer’s disease, the drugmaker said.

Like other drugs in its class, Kisunla also comes with potentially life-threatening side effects, which include brain swelling and brain bleeding. Although most cases identified in the trial were mild, ​​three deaths were linked to the drug, according to the FDA. Kisunla is now the second Alzheimer’s drug of its kind approved, behind Leqmebi. A third drug — Biogen’s Aduhelm — was taken off the market earlier this year.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Source: CNBC - 🏆 12. / 72 Read more »

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Source: NBCNewYork - 🏆 270. / 63 Read more »